Innovations in skin microphysiological systems for nonclinical testing and FDA modernization

Area of Science:

• Biotechnology
• Toxicology
• Dermatology

Background:

• Regulatory shifts favor alternatives to animal testing.
• Innovations in skin microphysiological systems (MPSs) are advancing preclinical research.
• Three key technologies are emerging: 3D bioprinting, skin organoids, and skin-on-a-chip.

Purpose of the Study:

• To review the development and applications of advanced skin MPSs.
• To highlight how these systems model human skin physiology and disease.
• To discuss their utility in toxicological screening and therapeutic evaluation.

Main Methods:

• Review of 3D bioprinting, skin organoids, and skin-on-a-chip technologies.
• Analysis of their capabilities in modeling skin barrier function, immune responses, and disease phenotypes.
• Examination of their use in toxicological and therapeutic assessments.

Main Results:

• These MPS platforms effectively replicate complex skin functions and disease models.
• They show significant utility in toxicological screening and evaluating new therapies.
• Emerging strategies involve automation and machine learning for high-content screening.

Conclusions:

• Skin MPSs are crucial for advancing research and preclinical applications, aligning with regulatory changes.
• These technologies provide robust models for understanding skin biology and disease.
• Future validation efforts may be guided by OECD test guidelines, with automation enhancing scalability.